IGF-1 LR3: A Synthetic Model of the Insulin-like Growth Hormone

IGF-1 LR3: A Synthetic Model of the Insulin-like Growth Hormone

by Dr. Usman | Jun 6, 2022 | Research

Research

IGF-1 LR3 and Cell Division

Speculations surrounding the peptide suggest it could be a powerful stimulant for cell proliferation and division. It is speculated to function in various tissues such as bone, liver, kidney, nerve, skin, blood, and lungs, potentially acting as a maturation hormone by speculatively promoting cell proliferation and differentiation. Due to the speculated prolonged half-life of IGF-1 LR3, it is believed to be a more potent molecule, with the potential for initiating cell activation three times more effectively compared to the impact of IGF-1 at the same concentration.

IGF-1 LR3 and Myostatin Interaction

Myostatin, considered to be a muscle growth inhibitor, may have its effects countered by the peptide, possibly inhibiting muscle degradation. This action is believed to occur through the activation of a muscle protein – MyoD, which is thought to regulate muscle dystrophy and become active in cases of tissue damage.

Fat Metabolism and Diabetes

By binding to the IGF-1R receptor and the insulin receptor, IGF-1 LR3 is thought to enhance fat metabolism indirectly. This speculative action may increase glucose uptake by the liver, muscle, and nerve, potentially triggering the breakdown of fatty tissues and leading to net energy consumption due to continuous glycogen and triglyceride degradation. Research studies suggest that the peptide may reduce blood sugar levels and insulin levels. In some instances, a 10% decrease in insulin required to balance blood sugar levels was reported. This decrease might offer insights into dealing with increased insulin levels in cases of low insulin sensitivity.

IGF-1 LR3 and Glucocorticoid Signaling

Glucocorticoid, a hormone considered to be secreted by the adrenal glands, may be controlled by IGF-1 LR3, according to speculative research. The research team proposed that the peptide may serve as a necessary ancillary in reducing the ancillary downstream impacts of glucocorticoids, including decreased bone density, muscle wasting, and fat cell storage.

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.

Latest Post

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis